VivoSeq
Other

Anal Fistula

25

Pipeline Programs↗

8

Active Trials↗

11

Companies Involved↗

Anal fistula is an emerging landscape with 25 programs across 11 companies. The most active players are AbbVie, Direct Biologics, LLC, Facet Biotech. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

71/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 1D

Direct Biologics, LLC

1 program

Phase 2F

Facet Biotech

1 program

Phase 2L

Lynch Biologics LLC

1 program

Phase 2J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

2 programs

Phase 2Bayer logo

Bayer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

20 of 28 classified programs — the dominant modality here.

29%ALL OTHERSCell therapy518%Monoclonal antibody27%Gene therapy14%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 33 pipeline programs.

Analysis

Trial Status

31

clinical trials

Completed15 · 48%
Recruiting6 · 19%
Terminated4 · 13%
Unknown status2 · 6%
Active, not recruiting2 · 6%
Withdrawn2 · 6%

Clinical Trials

Trial Activity

31 trials

Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas w/ Crohn's Disease
Recruiting·—·Phase 1·NCT05039411·5 enrolled
Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 1·NCT06902987·27 enrolled
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Recruiting·WWeill Medical College of Cornell University·Phase 1·NCT04190862·39 enrolled
Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients.
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·N/A·NCT07081373·408 enrolled
Evaluate the Distribution and Dynamic Behavior of TH-SC01 Cells in Vivo in Patients With Perianal Fistula
Recruiting·JJiangsu Topcel-KH Pharmaceutical Co., Ltd.·Phase 1·NCT06429241·8 enrolled
Tissue Therapy of Transsphincteric Anal Fistula
Recruiting·UUniversity of Southern Denmark·Phase 1/2·NCT06303752·75 enrolled
Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing
Active, not recruiting·—·Phase 2·NCT06632418·12 enrolled
Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)
Active, not recruiting·AAvobis Bio, LLC·Phase 2·NCT04847739·60 enrolled
Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula
Completed·Takeda logoTakeda·Phase 3·NCT04075825·150 enrolled
Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's
Completed·FFoundation for Liver Research·Phase 3·NCT00736983·76 enrolled
Randomized Control Trial of Micronized Purified Flavonoid Fraction for Post Operative Treatment in Anal Fistula Surgery
Completed·TTaipei Medical University Shuang Ho Hospital·Phase 4·NCT06184438·106 enrolled
Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)
Completed·MMayo Clinic·Phase 1·NCT02589119·15 enrolled
Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
Completed·VVanderbilt University Medical Center·Phase 4·NCT00517296·21 enrolled
Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease
Completed·—·Phase 3·NCT00475410·214 enrolled
A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease
Completed·—·Phase 2·NCT01316601·3 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)